Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by PATRICK M LYNCH and ERNEST HAWK.
PATRICK M LYNCH
Connection Strength
1.087
ERNEST HAWK
  1. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65(2):286-95.
    View in: PubMed
    Score: 0.533
  2. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun; 105(6):1437-43.
    View in: PubMed
    Score: 0.094
  3. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome. Clin Cancer Res. 2023 11 01; 29(21):4361-4372.
    View in: PubMed
    Score: 0.061
  4. Precancerous lesions of the digestive tract. The 18th Annual Symposium of the European Cancer Prevention Organization. Maastricht, The Netherlands. 12-14 October 2000. Abstracts. Eur J Cancer Prev. 2000 Dec; 9(6):443-63.
    View in: PubMed
    Score: 0.049
  5. Functional characterization of CNOT3 variants identified in familial adenomatous polyposis adenomas. Oncotarget. 2019 Jun 11; 10(39):3939-3951.
    View in: PubMed
    Score: 0.045
  6. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol. 2018 10 01; 29(10):2061-2067.
    View in: PubMed
    Score: 0.043
  7. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol. 2018 08 01; 4(8):1085-1092.
    View in: PubMed
    Score: 0.042
  8. Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis. Clin Cancer Res. 2017 Oct 01; 23(19):5936-5947.
    View in: PubMed
    Score: 0.039
  9. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila). 2016 06; 9(6):417-27.
    View in: PubMed
    Score: 0.036
  10. Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med. 2013 Jun; 2(3):391-402.
    View in: PubMed
    Score: 0.029
  11. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer. 2012 Jan; 3(1):16-22.
    View in: PubMed
    Score: 0.027
  12. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev. 2006 Jul; 15(7):1382-91.
    View in: PubMed
    Score: 0.018
  13. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):920-7.
    View in: PubMed
    Score: 0.016
  14. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res. 2004 Apr 15; 64(8):2904-9.
    View in: PubMed
    Score: 0.016
  15. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev. 2003 Aug; 12(8):755-62.
    View in: PubMed
    Score: 0.015
  16. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002 Jun; 50(6):857-60.
    View in: PubMed
    Score: 0.014
  17. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000 Jun 29; 342(26):1946-52.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.